Healthcare

India’s latest budget has placed health care and biopharmaceutical innovation at the center of its growth strategy, signaling a long-term commitment to research-driven development and public health resilience. Enhanced allocations, targeted incentives, and policy reforms aim to strengthen domestic manufacturing, accelerate innovation, and reduce import dependence in critical segments. The focus extends from drug discovery and biotechnology research to digital health and advanced medical infrastructure.

Obesity-focused medications are rapidly becoming a defining growth driver for the global pharmaceutical industry, with Indian drugmakers positioning themselves to capture a share of this expanding market. Rising lifestyle-related disorders, increasing awareness of metabolic health and growing affordability are reshaping treatment demand. Sun Pharma, India’s largest drug manufacturer by market value, is among the companies aligning its long-term strategy with this shift.

MOVIN, the logistics venture formed by InterGlobe Enterprises and UPS, has expanded its service portfolio to enter India’s rapidly growing healthcare logistics market. With demand for time-sensitive, temperature-controlled, and compliant medical shipments climbing across the country, the company aims to provide high-precision supply-chain solutions for pharmaceuticals, diagnostics, medical devices, and hospital networks. Its entry comes as healthcare manufacturers and distributors seek more reliable nationwide coverage and integrated cold-chain capabilities.

Union Health Minister J.P. Nadda underscored the pivotal role of food safety regulators in safeguarding public health and maintaining high standards across India’s food supply chain. Speaking at a national food safety conference, he highlighted the importance of rigorous inspection protocols, technological adoption, and stringent compliance enforcement to prevent contamination and ensure consumer trust.